Table 3 Current ongoing early phase I/II trials with EGFR inhibitors
From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
EGFR inhibitors | ||||
|---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (phase) | Study design | Disease |
Aflutinib (ASK120067) | EGFR T790M Inhibitor | NCT03502850 (1/2) | Monotherapy | EGFR mutant NSCLC progression on first line therapy due to T790M |
BDTX-189 | EGFR/HER2 Inhibitor | NCT04209465 (1/2) | Monotherapy | EGFR and HER2/3 mutated solid cancers |
CLN-081 (TAS6417) | Pan-EGFR Inhibitor | NCT04036682 (1/2) | Monotherapy | EGFR exon 20 mutated NSCLC |
D-0316 | EGFR T790M Inhibitor | NCT04206072 (2/3) | Monotherapy | EX19del, L858R mutated NSCLC adenocarcinoma |
Dacomitinib | Pan-EGFR inhibitor | NCT03755102 (1) | Monotherapy or in combination with Osimertinib | EGFR mutant NSCLC |
DZD9008 | Wild type EGFR and HER2 Inhibitor | NCT03974022 (1/2) | Monotherapy | EGFR/HER2 mutated NSCLC |
FCN-411 | EGFR, HER2 and HER4 Inhibitor | NCT03420079 (1/2) | Monotherapy | EGFR mutant NSCLC |
JNJ-61186372 | Bispecific antibody binding to EGFR and cMET | NCT02609776 (1) | Monotherapy or in combination with Lazertinib and Carboplatin/Pemetrexed | EGFR or MET mutant/amplified NSCLC |
Nazartinib (EGF816) | Irreversible selective mutant specific EGFR Inhibitor | NCT03292133 (2) | Combination with Gefitinib | EGFR mutant NSCLC |
Nazartinib (EGF816) | Irreversible selective mutant specific EGFR Inhibitor | NCT03516214 (1) | Combination with Trametinib | EGFR mutant (del19 or p.L858R) NSCLC |
Necitumumab | Anti EGFR mAB | NCT02496663 (1) | Combination with Osimertinib | EGFR mutant NSCLC |
Osimertinib | Potent mutant EGFR Inhibitor | NCT03434418 (2) | Monotherapy | NSCLC with uncommon EGFR mutations (EGFR 18;G719X, EGFR 20;S7681, EGFR 21;L861Q) |
Tarloxotinib | Hypoxia activated prodrug (TH-4000) wild type EGFR Inhibitor | NCT03805841 (2) | Monotherapy | EGFR exon 20 and HER2 activating mutant NSCLC |
WSD0922-FU | EGFR/EGFRvIII Inhibitor | NCT04197934 (1) | Monotherapy | EGFR mutant NSCLC |
ZN-e4 (KP-673) | EGFR Inhibitor including T790M | NCT03446417 (1/2) | Monotherapy | EGFR mutant NSCLC |